Ovid Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was USD 1.46 million compared to USD 208.38 million a year ago. Net loss was USD 42.66 million compared to net income of USD 148.83 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to basic earnings per share from continuing operations of USD 2.15 a year ago. Diluted loss per share from continuing operations was USD 0.61 compared to diluted earnings per share from continuing operations of USD 2.14 a year ago.